[Courtesy of Samsung Biologics]
Samsung BioLogics said in a statement on Monday that it has successfully performed "N-1 perfusion" with an alternating tangential flow (ATF) device to supply the commercial production process at its manufacturing site in Songdo west of Seoul.
Clients can leverage another innovative offering to boost their clinical and commercial production capability in addition to the comprehensive array of biopharmaceutical development, manufacturing, and testing services, the company said, adding they may choose from a more diversified portfolio of manufacturing options.
Samsung Biologics said that although perfusion is gaining broader biopharmaceutical application at small scale with clinical development, few companies have reported utilization at large scale for commercial applications to intensify bioprocessing and boost productivity.
The ATF perfusion system allows for contract development and manufacturing organizations (CDMOs) to cultivate higher cell culture densities by up to 10 fold while retaining high cell viabilities at the seed stage to enable inoculation of the production bioreactors at higher cell densities and achieve peak cell densities within shorter culture durations.
A contract manufacturing organization (CMO), sometimes called CDMO, is a company that serves other companies in the pharmaceutical industry to provide comprehensive services from development through manufacturing. The popularity of pharmaceutical outsourcing has grown and companies are increasingly outsourcing to CDMOs due to the benefits outside expertise can bring to their business.
"This allows for improved productivity and reduction in production time," Samsung Biologics said, adding the perfusion cultivation has been developed in full automation mode by integrating the ATF system with the bioreactor control logics so that manual intervention is reduced to a minimum during the cultivation duration.
reporter
Lim Chang-won
cwlim34@ajunews.com
